

NEVADA CANCER RESEARCH FOUNDATION NCORP/AFFILIATE SITES

ACTIVE PROTOCOL LISTING 1/06/2021

For Patient Registration and Eligibility Information, Call 702-384-0013

PLEASE CALL Shannon Yule @ 702-384-0013 or Download our app NCRF on iOS and Android for protocol information

Investigational Drug Provided-**B**olded (S) Surgery (RS) Radiosurgery (*) Recruitment Material (P) Pharm Study (+) RT Credentialing Required (1572) 1572 Limited Participation (CC) Cancer Control Protocol

DISEASE CATEGORY	PROTOCOL	DESCRIPTION	OPEN AT:
Cancer Control/Symptom Management			
Prevention of Chemotherapy Induced Nausea and Vomiting	Alliance A221602 (CC)	Palonosetron/Ondansetron + Dexamethasone + Olanzapine + Fosaprepitant v. Placebo	CIRB
NCI COVID-19 in Cancer Patients Study (NCCAPS) AYA-No Age Restrictions	NCI COVID-19 (CC)	SARS CoV-2 Positive; Data, Imaging and Specimen Collection	CIRB
National Biorepository to Advance Studies of Immune-Related AEs	Alliance A151804 (CC)	Grade 3+ irAE Event → Registration → Collection of Biospecimens and Data	CIRB
Treatment of Refractory Nausea	URCC 16070 (CC)	C1: Standard of Care → C2: A + D + P v. A + D + P + Comp v. A + D + Z + P	CIRB
Engendering Reproductive Health within Oncologic Survivorship (EROS)	ECOG E1Q11 (CC) (1572)	Standard Practice v. Training Modules Algorithm, Referral Development – For Women Ages 18-55	CIRB
Phase II Cognitive Impairment in Patients Receiving Chemotherapy	URCC 16092 (CC)	Ibuprofen v. Placebo **PROTOCOL TRAINING REQUIRED**	CIRB
Solid Tumor or Lymphoma with Tissue Available			
Molecular Analysis for Therapy Choice (MATCH)	ECOG-ACRIN EAY131	Screening → Targeted Molecular Treatment → Follow up v. Rescreen and Retreatment → Follow up	CIRB
DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors	SWOG S1609	Ipilimumab + Nivolumab	CIRB
Brain			
Phase III, Patients with 5-15 Brain Metastases	CCTG CE.7 (+) (RS)	HA-WBRT in 10 Fractions + Memantine v. SRS in Single Fraction	CIRB
1p/19q Co-Deleted Anaplastic Glioma or Low Grade Glioma	NCCTG N0577 (+)	Temozolomide Alone v. RT w/Concomitant + Adjuvant Temozolomide v. RT w/Adjuvant PCV Chemotherapy	CIRB
Breast			
Neoadjuvant:			
Stage II or IIIA HER2 + Invasive Breast Cancer ER/PR +/-	ECOG-ACRIN EA1181(+,S)	THP 4 Cycles → Surgery → pCR: HP 1 Yr + RT & Endocrine Rx v. No pCR: SOC (Physician Discretion)	CIRB
Comparing ALND to Axillary XRT with Positive SLND After Neoadjuvant Chemo	Alliance A011202 (+)	ALND + Nodal XRT (w/o XRT to dissected axilla) v. Axillary XRT and Nodal XRT	CIRB
Adjuvant:			
Phase III, Hypofractionated Post Mastectomy RT w/Breast Reconstruction	Alliance A221505 (+)	Mastectomy → Randomization to Conventional PMRT v. Hypofractionated PMRT	CIRB
Cancer-Related Fatigue, Previously Treated Breast Cancer in Women	URCC 18007 (CC)	Bupropion v. Placebo	CIRB
DTL TNBC-Residual Invasive CA or Positive Lymph Nodes After Neoadjuvant Chemo	SWOG S1418	Pembrolizumab v. Observation **PROTOCOL TRAINING REQUIRED**	CIRB
Stage II or III Node + HER2 -: ABC Trial Companion	Alliance A211601	Evaluation of Mammographic Breast Density Effect of Aspirin (Companion to A011502)	CIRB
Evaluating Weight Loss of Overweight Obese Women ER/PgR +/- HER2-	Alliance A011401 (CC)	2 Year Health Education Intervention +/- Supervised Weight Loss Intervention	CIRB
Residual Triple-Negative, Basel-Like Following Neoadjuvant Chemo	ECOG-ACRIN EA1131	Carboplatin or Cisplatin (Physician choice) v. Capecitabine	CIRB
Phase III Adjuvant Node (+) or High-Risk Node (-) Triple (-) Invasive Breast	NRG-BR003 (+)	Doxorubicin + Cyclophosphamide → Paclitaxel +/- Carboplatin	CIRB
Metastatic:			
Her2 Positive w/Current of Planned Her2 Targeted Therapy w/Trastuzumab	SWOG S1501	Echo → Stratification → Observation v. Carvedilol **ECHO LAB VALIDATION REQUIRED**	CIRB
DTL Her2 Positive Metastatic Breast Cancer ER/PgR +/- **PROTOCOL TRAINING**	NRG-BR004	Paclitaxel + Trastuzumab + Pertuzumab +/- Atezolizumab/Placebo	CIRB
Gastrointestinal			
Anal:			
Phase II, Early Stage Anal Squamous Cell Carcinoma (DECREASE)	ECOG-ACRIN EA2182 (+)	Standard RT + Concurrent Chemo v. De-Intensified RT + Concurrent Chemo	CIRB
DTL Phase II, High Risk Invasive Anal Squamous Cell Carcinoma	ECOG-ACRIN EA2165 (+)	Combined Modality Therapy (Physician Choice) → Nivolumab v. Observation	CIRB
Colon:			
DTL Previously Untreated Metastatic Colorectal Cancer (SOLARIS)	Alliance A021703	mFOLFOX6 or FOLFIRI + Bevacizumab with High Dose v. Standard Dose Vitamin D3/Placebo	CIRB
DTL Stage III Colon Cancer with Deficient DNA Mismatch Repair (dMMR)	Alliance A021502	dMMR Status → Rand: mFOLFOX6 + Atezolizumab → Atezolizumab Alone v. mFOLFOX6 Alone	CIRB
Advanced/Metastatic Colorectal with HER-2 Amplification	SWOG S1613	HER 2-Amplification Screening → Randomization: Trastuzumab + Pertuzumab v. Cetuximab + Irinotecan → Optional Crossover: Trastuzumab + Pertuzumab	CIRB
Pancreas:			
Phase III Resectable Pancreatic Cancer	Alliance A021806 (+)	Pre-Reg: PDAC Confirmed by IROC Ohio → Reg: Surgery → mFOLFIRINOX v. mFOLFIRINOX → Surgery	CIRB
Other:			
Locoregional Esophageal & Gastroesophageal Junction Adenocarcinoma	ECOG-ACRIN EA2174 (+)	Step 1: Carboplatin + Paclitaxel + RT + Optional DWI-MRI +/- Nivolumab → Esophagectomy → Step 2: Nivolumab v. Nivolumab + Ipilimumab	CIRB
Phase III Newly Diagnosed, Advanced Biliary Tract Cancers	SWOG S1815	Gemcitabine + Cisplatin +/- Nab-Paclitaxel	CIRB
Phase III Oligometastatic HER2 (-) Esophageal and Gastric Adeno.	ECOG-ACRIN EA2183	FOLFOX v. CAPOX (Physician Choice) → Step 2: XRT + FOLFOX v. FOLFOX v. XRT + CAPOX v. CAPOX	CIRB
Advanced Intrahepatic Cholangiocarcinoma	ECOG-ACRIN EA2187	Pevonedistat + Carboplatin + Paclitaxel → Pevonedistat v. Pevonedistat Alone	CIRB
DTL Phase III Advanced/Unresectable NET Pancreatic or Non-Pancreatic Origin	Alliance A021602	Cabozantinib v. Placebo (After Progression on Everolimus)	CIRB
Advanced G3 Non-Small Cell Gastroenteropancreatic Neuro. Carcinomas	ECOG-ACRIN EA2142	Capecitabine + Temozolomide v. Cisplatin + Etoposide or Carboplatin + Etoposide	CIRB
Genitourinary			
Phase II Rare Genitourinary Tumors (ICONIC)	Alliance A031702	Cabozantinib (C) + Nivolumab (N) + Ipilimumab (4 Cycles-q 3 Weeks) → C + N (q 4 Weeks-Maintenance)	CIRB

DISEASE CATEGORY	PROTOCOL	DESCRIPTION	OPEN AT:
Prostate:			
Phase III, Post-Prostatectomy Biochemical Recurrence (INDICATE)	ECOG-ACRIN EA8191 (+)	Register: PET/CT: Negative Pelvic Mets on PET: SOC RT + STAD +/- Apalutamide v. Positive Pelvic Mets on PET: SOC RT + STAD + Apalutamide +/- Directed Therapy	CIRB
Phase III, Node Positive, After Radical Prostatectomy	NRG-GU008 (+)	RT + GnRH Agonist/Antagonist x 2years +/- Abiraterone Acetate + Prednisone + Apalutamide	CIRB
Phase II/III RT and ADT Post Prostatectomy	NRG-GU002 (+)	Step 1: DECIPHER Prostatectomy Analysis → Step 2: RT + ADT +/- Docetaxel	CIRB
Patient Who Receive Both RT and ADT **PROTOCOL TRAINING REQUIRED**	NRG-CC007CD	Treatment Plan + Survivorship Care Plan v. Survivorship Care Plan	CIRB
Metastatic Prostate Cancer	SWOG S1802 (+)	Standard Systemic Therapy +/- Definitive Treatment (Surgery of Radiation)	CIRB
Extensive Disease Following Docetaxel: CHAARTED2 Trial	ECOG-ACRIN EA8153	Abiraterone + Prednisone v. Abiraterone + Prednisone + Cabazitaxel	CIRB
Renal:			
Phase III Metastatic Renal Cell Carcinoma (PROBE TRIAL)	SWOG S1931	Step 1: Immunotherapy Treatment → Urology Consult → Step 2: Continued Systemic Immunotherapy +/- Cytoreductive Nephrectomy	CIRB
Phase III, Metastatic Untreated Renal Cell Cancer (PDIGREE)	Alliance A031704	Nivolumab + Ipilimumab → Nivolumab +/- Cabozantinib	CIRB
Phase II, TFE/Translocation Renal Cell Carcinoma (tRCC) AYA-Age: ≥ 12 months	COG AREN1721	Axitinib + Nivolumab v. Axitinib v. Nivolumab	CIRB
DTL RCC Undergoing Nephrectomy (PROSPER RCC)**1572 + PHYSICIAN TRAINING*	ECOG-ACRIN EA8143	Nivolumab → Nephrectomy → Nivolumab v. Nephrectomy → Observation	CIRB
Bladder:			
DTL Localized Muscle Invasive Bladder Cancer **PROTOCOL TRAINING REQUIRED**	SWOG S1806 (+)	Chemotherapy (Physician Choice) + RT +/- Atezolizumab	CIRB
Phase III Adjuvant Muscle-Invasive Urothelial of the Bladder or Upper Tract	Alliance A031501	Pembrolizumab v. Observation	CIRB
Germ Cell Tumors			
Newly DX, Observational Cohort to Assess miRNA 371 for Outcome Prediction	SWOG S1823 (CC)	Baseline Biospecimen → Biospecimen Schedule Based on Low, Moderate, or High Risk of Relapse	CIRB
Phase III, Standard Risk AYA Study-AYA Age: 0-50	COG AGCT1531	Registration → Surgery → Reevaluate → Randomization → BEC v. BEP → Follow Up	CIRB
Phase III, Intermediate and Poor-Risk Metastatic-AYA Age: 11-45	COG AGCT1532	Accelerated BEP v. Standard BEP	CIRB
Gynecological			
Platinum Resistant Ovarian Cancer	NRG-GY009	Liposomal Doxorubicin + Atezolizumab v. Liposomal Doxorubicin + Bevacizumab +/- Atezolizumab	CIRB
Randomized, Phase III, Stage I-IIA Cervical CA with Intermediate Risk Factors	GOG 0263 (+)	Standard Pelvic RT or IMRT v. Concurrent Cisplatin and Pelvic RT or IMRT	CIRB
Head And Neck			
Phase II/III Locally Advanced, Intermediate Risk HPV + Oropharynx Cancer	ECOG-ACRIN EA3161 (+)	Cisplatin + RT → Nivolumab v. Observation → Nivolumab	CIRB
Early Stage, p16 Positive, Non-Smoking Associated Oropharyngeal Cancer **PROTOCOL TRAINING REQUIRED**	NRG-HN005 (+)	RT 70 Gy 6 wks 6 Fractions + Cisplatin v. RT 60 Gy 6 wks 5 Fractions + Cisplatin v. RT 60 Gy 5 wks 6 Fractions per wk + Nivolumab	CIRB
DTL Untreated, Unresected Head and Neck Cancers	NRG-HN004 (+)	RT + Cetuximab v. RT + MEDI4736 (Durvalumab)	CIRB
Treatment of Stage II-IVB Nasopharyngeal Carcinoma for Patients with Detectable EBV DNA and Undetectable EBV DNA	NRG-HN001 (+)	Registration: Cisplatin + IMRT, Randomization:: Detectable EBV DNA: Cisplatin + 5FU v. Gemcitabine + Paclitaxel; Undetectable EBV DNA: Cisplatin + 5FU v. Observation	CIRB
Hematological			
Phase II Ph-Negative CD22-Positive B-lineage ALL	Alliance A041703	Induction: Inotuzumab Ozogamicin → Consolidation: Blinatumomab	CIRB
Phase I/II Relapsed or Refractory T-ALL or T-LBL	SWOG S1905	SOC IT Chemotherapy with Methotrexate + OBI-3424	CIRB
Newly Diagnosed Precursor B-Cell ALL-AYA Study Age: 18-39	Alliance A041501	SOC +/- Inotuzumab Ozogamicin BMX Required-Must call NCRF CRA for Slot Reservation prior to BMX	CIRB
DTL Phase II/III Intensive Induction Chemo for AML Adults Age: ≥ 60	Alliance A041701	Ind: Daunorubicin + Cytarabine +/- Uproleselan → Cons: Cytarabine +/- Uproleselan	CIRB
Untreated CLL in Patient Age: ≥ 18 but < 70	ECOG-ACRIN EA9161	Ibrutinib + Obinutuzumab +/- Venetoclax	CIRB
Phase II, Chronic Phase CML with Molecular Evidence of Disease	SWOG S1712	Single Agent TKI: Dasatinib or Nilotinib +/- Ruxolitinib	CIRB
The National Myelodysplastic Syndrome (MDS) Study **PROTOCOL TRAINING REQUIRED**	ECOG-ACRIN NHLBI-MDS	Suspect MDS or MDS/MPN or De Novo or Therapy-Related MDS w/in 6-mos. of Enrollment. BMBX w/in 1 wk of Reg. No prior MDS TX at Entry. No Hem GF in Prior 6 mos. AML <30% Blasts w/o Core Binding Factor	CIRB
Lung			
Small Cell:			
DTL Phase II/III ES-SCLC, SD, or PR After 4-6 Cycles of E/P doublet + Atezolizumab	NRG-LU007 (+)	Atezolizumab +/- Radiation Therapy	CIRB
Phase II/III Defined as Limited-Stage or Extensive-Stage SCLC	NRG-CC003 (+)	Prophylactic Cranial Irradiation +/- Hippocampal Avoidance Using IMRT	CIRB
Phase II, SLFN11 Positive Extensive Stage SCLC	SWOG S1929	Step 1: SLFN11-Positive → Step 2: Atezolizumab v. Atezolizumab + Talazoparib	CIRB
DTL Phase II/III Limited Stage SCLC **PROTOCOL TRAINING REQUIRED**	NRG-LU005 (+)	Platinum with Etoposide x 4 Cycles + RT +/- Atezolizumab Starting with Cycle 2	CIRB
Non-Small Cell:			
Phase II, NSCLC in Older Patients Age: ≥ 70 **GERIATRIC TRAINING**	Alliance A171901	First-Line Pembrolizumab +/- Chemotherapy (Physicians Choice)	CIRB
Unresectable Stage 3 NSCLC	ECOG-ACRIN EA5181 (+)	Concurrent Chemotherapy (Physician Choice) + Radiotherapy +/- Durvalumab	CIRB
Randomized Phase II Previously Treated Non-Squamous NSCLC	ECOG-ACRIN EA5191	Cabozantinib v. Cabozantinib + Nivolumab v. Standard Chemotherapy, Physician's Choice	CIRB
1st Line Immunotherapy Alone or in Combination with Chemo in Induction / Maintenance or Post Progression in Advanced Non Squamous: INSIGNA Study	ECOG-ACRIN EA5163	Pembrolizumab v. Induction: Pembrolizumab → Pemetrexed → Carboplatin → Maintenance: Pembrolizumab → Pemetrexed	CIRB
Phase II/III Metastatic NSCLC	NRG-LU002 (+)	4 Cycles 1st Line Therapy → Restaging → Randomize → Maintenance v. SBRT → Maintenance	CIRB

DISEASE CATEGORY	PROTOCOL	DESCRIPTION	OPEN AT:
Completely Resected IB, II or IIIA Non-Squamous NSCLC **CREDENTIALING REQUIRED FOR A081801**	ALCHEMIST; A151216, E4512, A081801	A151216: Tissue Screening → Biomarker Driven Stratification → Chemo: E4512; Crizotinib v. Observ., A081801: Platinum doubl. +/- Pembro. → +/- PORT → Pembro v. Observ	CIRB
Biomarker-Driven Therapies & Immunotherapies in Previously-Treated NSCLC **PROTOCOL TRAINING REQUIRED** **DTL Required for ALL Sub-Studies**	LUNGMAP; S1900B	LUNGMAP: Tissue Screening → Strat. → Chemo: S1900B: LOXO-292	CIRB
Lymphoma (Non-Hodgkin's Lymphoma)			
Newly Diagnosed Stage III-IV Hodgkin Lymphoma-AYA Study Age: ≥ 12	SWOG S1826 (+)	Nivolumab +AVD v. Brentuximab Vedotin + AVD x 6 Cycles	CIRB
Mantel Cell in Minimal Residual Disease-Negative, 1 st Complete Remission	ECOG-ACRIN EA4151 (+)	Step 0; Tumor Submission → Step 1; Auto HCT + Rituximab v. Rituximab	CIRB
Phase II Early Relapsed or Refractory Follicular Lymphoma **TRAINING REQ**	SWOG S1608	TGR-1202 + Obinutuzumab (O) v. Lenalidomide + O v. CHOP or Bendamustine + O	CIRB
Phase II Relapsed or Refractory Hodgkin's Lymphoma-AYA Age: ≥ 12	ECOG-ACRIN E4412	Nivolumab + Brentuximab +/- Ipilimumab v.	CIRB
Melanoma/Merkel			
Unresectable State III or IV **Nivolumab and Ipilimumab Training Required**	ECOG-ACRIN EA6141	Nivolumab + Ipilimumab + GM-CSF → Nivolumab + GM-CSF v. Nivolumab + Ipilimumab → Nivolumab	CIRB
DTL Phase II, Advanced Cutaneous Squamous Cell Cancer of the Skin (cSCC)	Alliance A091802	Avelumab → Re-Register → Avelumab + Cetuximab v. Avelumab + Cetuximab → Avelumab Alone	CIRB
Phase III Completely Resected Merkel Cell Carcinoma	ECOG-ACRIN EA6174 (+)	Pembrolizumab v. Standard of Care Observation	CIRB
Phase II Clinically Detectable Stage III-IV High Risk Melanoma	SWOG S1801	Adjuvant v. Neoadjuvant Pembrolizumab	CIRB
Advanced BRAFV600 Mutant Melanoma **IPILIMUMAB TRAINING REQUIRED**	ECOG-ACRIN EA6134	Dabrafenib (D) + Trametinib (T) → Ipilimumab (I) + Nivolumab (N) at Prog. v. I + N → D + T at Prog.	CIRB
Myeloma			
High-Risk Smoldering Multiple Myeloma	ECOG-ACRIN EAA173	Lenalidomide + Dexamethasone +/- Daratumumab	CIRB
Sarcoma			
Phase III, Intermediate Risk, Rhabdomyosarcoma-AYA Age: ≤ 40	COG ARST1431	VAC Alternating with VI +/- Temozolomide **RESERVATION REQUIRED**	CIRB
Thymic			
Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma	SWOG S1701	Carboplatin + Paclitaxel +/- Ramucirumab	CIRB